DDRDRug Study Template

Name of Student Nurse: Aaron Gerald Barrer Date: January 8, 2021

Level/Block/Group: II-20 Clinical Instructor: Kharissa Mae Launico Ugaban

NAME OF DRUG MECHANISM OF CONTRAINDICATIONS SIDE EFFECTS ADVERSE EFFECTS NURSING

ACTION RESPONSIBILITIES

GENERIC NAME Inhibits hepatic  Hypersensitivity to drug  constipation CNS: headache,  Watch closely for
enzyme HMG-CoA or its components  stomach pain asthenia myositis and other
reductase,  nausea adverse musculoskeletal
GI: nausea, vomiting,
interrupting  Active hepatic disease or  headache reactions. Know that
Simvastatin diarrhea, constipation,
cholesterol unexplained persistent  memory loss or drug may cause
abdominal pain or
synthesis and low- serum transaminase forgetfulness rhabdomyolysis.
cramps, flatulence,
density lipoprotein elevations  confusion
BRAND NAME dyspepsia
(LDL) consumption.  itchy or red skin  Monitor liver function
Apo-Simvastatin, Co Net effect is total Musculoskeletal: tests, CBC, and lipid
Simvastatin, Dom- cholesterol and  Concurrent use of myalgia, levels.
Simvastatin, serum triglyceride cyclosporine, danazol, rhabdomyolysis
GenSimvastatin, Novo- reductions. gemfibrozil, or strong  In patients receiving
Simvastatin, Nu- CYP3A4 inhibitors Respiratory: upper warfarin concurrently,
Simvastatin, PHL- respiratory infection closely monitor
Simvastatin*, PMS-  Women who are prothrombin time and
Simvastatin, Ranzolont , pregnant or may become International
Ratio-Simvastin, pregnant Normalized Ratio.
RivaSimvastatin, Sandoz
Simvastatin, Simvador ,  Advise patient to take
Zoco  Breastfeeding patients with evening meal, but
not with large amounts
CLASSIFICATION of grapefruit juice.

 Tell patient drug may

Pharmacologic class:
take up to 4 weeks to be
HMG-CoA reductase effective.
inhibitor

Therapeutic class:  Instruct patient to avoid

Antihyperlipidemic alcohol use.
Pregnancy risk category X
 As appropriate, review
 INDICATION
Adjunct to diet to reduce
risk of coronary heart
disease (CHD) deaths,
cardiovascular events, and
hyperlipidemia
all other significant and
life-threatening adverse
reactions and
interactions, especially
those related to the
drugs, tests, foods,
herbs, and behaviors
mentioned above.

DOSAGE & FREQUENCY

Initially, 10 to 20 mg P.O.
daily in the evening. For
patients at high risk for a
CHD event due to existing
CHD, diabetes, peripheral
vessel disease, or history
of stroke or other
cerebrovascular disease,
initial dosage is 40
mg/day. Range is 5 to 40
mg/day. Restrict use of
80-mg dose to patients
who have been taking
simvastatin 80 mg long
term (for example, for 12
months or more) without
evidence of muscle
toxicity. Patients unable to
achieve their LDL-C goal
utilizing 40-mg dose
should not be titrated to
80-mg dose, but should be
placed on alternative LDL-
C–lowering treatment that
provides greater LDL-C
lowering effects.